2014
Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation
Kluger MD, Halazun KJ, Barroso RT, Fox AN, Olsen SK, Madoff DC, Siegel AB, Weintraub JL, Sussman J, Brown RS, Cherqui D, Emond JC. Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation. Liver Transplantation 2014, 20: 536-543. PMID: 24493271, PMCID: PMC4095977, DOI: 10.1002/lt.23846.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinoma, HepatocellularCase-Control StudiesChemoembolization, TherapeuticDisease-Free SurvivalEnd Stage Liver DiseaseFemaleHumansKaplan-Meier EstimateLiver NeoplasmsLiver TransplantationMaleMiddle AgedNeoplasm Recurrence, LocalRetrospective StudiesTime FactorsTreatment OutcomeConceptsWait-list dropoutTAE patientsTACE patientsTransarterial embolizationTransarterial chemoembolizationHCC patientsEnd-stage liver disease (MELD) scoreSurvival rateRecurrence-free survival ratesMethods of embolizationRadiographic tumor sizeLiver Disease scoreOverall survival rateRecurrence-free survivalKaplan-Meier survivalBland transarterial embolizationCase-control studySignificant demographic differencesExplant tumorsPrimary endpointTreat basisTumor sizeHepatocellular carcinomaDisease scorePatients
2010
Response, Survival, and Prognostic Factors After Hepatic Arterial Chemoembolization in Patients With Liver Metastases From Cutaneous Melanoma
Ahrar J, Gupta S, Ensor J, Ahrar K, Madoff DC, Wallace MJ, Murthy R, Tam A, Hwu P, Bedikian AY. Response, Survival, and Prognostic Factors After Hepatic Arterial Chemoembolization in Patients With Liver Metastases From Cutaneous Melanoma. Cancer Investigation 2010, 29: 49-55. PMID: 21166498, DOI: 10.3109/07357907.2010.535052.Peer-Reviewed Original ResearchConceptsHepatic artery chemoembolizationOverall survivalCutaneous melanoma metastaticExtrahepatic metastatic sitesHepatic arterial chemoembolizationMedian overall survivalLactate dehydrogenase levelsType of treatmentMelanoma metastaticRadiologic responseDisease stabilizationLiver metastasesMost patientsPatient ageArterial chemoembolizationPrognostic factorsLiver diseaseMetastatic sitesCutaneous melanomaMedical recordsDehydrogenase levelsPatientsSignificant predictorsChemoembolizationSurvival
2009
Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival
Palavecino M, Chun YS, Madoff DC, Zorzi D, Kishi Y, Kaseb AO, Curley SA, Abdalla EK, Vauthey JN. Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival. Surgery 2009, 145: 399-405. PMID: 19303988, DOI: 10.1016/j.surg.2008.10.009.Peer-Reviewed Original ResearchConceptsPreoperative portal vein embolizationMajor hepatic resectionPreoperative PVEPVE groupHepatic resectionPortal vein embolizationHepatocellular carcinomaPerioperative outcomesDFS ratesPerioperative deathsVein embolizationSurvival rateDisease-free survival ratesPreoperative transarterial chemoembolizationOverall postoperative complicationsRemnant liver volumeImproved perioperative outcomesOverall survival rateAmerican Joint CommitteeHepatitis B virusHepatitis C virusPerioperative mortalityPerioperative riskPostoperative complicationsOverall survival
2007
Systemic Chemotherapy and Two-Stage Hepatectomy for Extensive Bilateral Colorectal Liver Metastases: Perioperative Safety and Survival
Chun YS, Vauthey JN, Ribero D, Donadon M, Mullen JT, Eng C, Madoff DC, Chang DZ, Ho L, Kopetz S, Wei SH, Curley SA, Abdalla EK. Systemic Chemotherapy and Two-Stage Hepatectomy for Extensive Bilateral Colorectal Liver Metastases: Perioperative Safety and Survival. Journal Of Gastrointestinal Surgery 2007, 11: 1498-1505. PMID: 17849166, DOI: 10.1007/s11605-007-0272-2.Peer-Reviewed Original ResearchConceptsBilateral colorectal liver metastasesColorectal liver metastasesPreoperative portal vein embolizationTwo-stage hepatectomyGroup IGroup IISystemic chemotherapyLiver metastasesSurvival rateDisease-free survival ratesBackgroundTwo-stage hepatectomyDay postoperative mortalityOne-stage hepatectomyPreoperative systemic chemotherapyGroup II patientsMedian hospital stayOutcomes of patientsPortal vein embolizationTreatment of patientsSecond-stage hepatectomyPostoperative mortalityAggressive surgeryBilateral diseaseHospital stayMajor hepatectomy
2006
Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors
Kobayashi K, Gupta S, Trent JC, Vauthey J, Krishnamurthy S, Ensor J, Ahrar K, Wallace MJ, Madoff DC, Murthy R, McRae SE, Hicks ME. Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors. Cancer 2006, 107: 2833-2841. PMID: 17096432, DOI: 10.1002/cncr.22336.Peer-Reviewed Original ResearchConceptsHepatic artery chemoembolizationGastrointestinal stromal tumorsUse of imatinibOverall survivalOS timeLiver diseaseStromal tumorsTumor responseMetastatic gastrointestinal stromal tumorsExtensive liver involvementMedian OS timeObjective tumor responseMedian PFS timeProgression-free survivalKaplan-Meier methodMajority of patientsDurable tumor responsesExtrahepatic diseaseOS ratesRadiologic responseStable diseaseDisease stabilizationPFS timeExtrahepatic metastasesLiver involvement
2005
Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors
Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, McRae SE, Hicks ME, Rao S, Vauthey J, Ajani JA, Yao JC. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors. Cancer 2005, 104: 1590-1602. PMID: 16134179, DOI: 10.1002/cncr.21389.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoid TumorCarcinoma, Islet CellChemoembolization, TherapeuticDisease-Free SurvivalEmbolization, TherapeuticFemaleFollow-Up StudiesHepatic ArteryHumansLiver NeoplasmsMaleMedical RecordsMiddle AgedPrognosisRetrospective StudiesRisk FactorsSurvival RateConceptsHepatic arterial embolizationProgression-free survivalIslet cell carcinomaMetastatic neuroendocrine tumorsIntact primary tumorOverall survivalCarcinoid tumorsCell carcinomaHigh response rateNeuroendocrine tumorsMultivariate analysisArterial embolizationBone metastasesPrimary tumorMale genderRisk factorsPrognostic variablesResponse rateOnly independent risk factorLonger progression-free survivalPancreatic islet cell carcinomaExtensive liver diseaseOutcomes of patientsIndependent risk factorOnly risk factor